Preimplantation Genetic Testing Market by Technology (Comparative Genomic Hybridization, Fluorescence in-Situ Hybridization, Next-Generation Sequencing), Offering (Instruments, Reagents & Consumables, Software & Services), Procedure Type, Application, End
Description
Preimplantation Genetic Testing Market by Technology (Comparative Genomic Hybridization, Fluorescence in-Situ Hybridization, Next-Generation Sequencing), Offering (Instruments, Reagents & Consumables, Software & Services), Procedure Type, Application, End User - Global Forecast 2024-2030
The Preimplantation Genetic Testing Market size was estimated at USD 728.40 million in 2023 and expected to reach USD 829.06 million in 2024, at a CAGR 14.56% to reach USD 1,886.28 million by 2030.
Preimplantation genetic testing (PGT) refers to technologies used to detect chromosomal abnormalities affecting the embryos before implantation. PGT is a crucial service that allows for early detection of genetic abnormalities in embryos before implantation during in-vitro fertilization (IVF) procedures, significantly reducing the risk of passing on inheritable diseases to offspring and improving IVF success rates. The primary application areas for PGT include identifying monogenic disorders, chromosomal abnormalities, mitochondrial diseases, and human leukocyte antigen (HLA) matching for potential siblings. The rising infertility rates due to lifestyle changes and delayed parenthood choices among couples have necessitated the development of PGT technologies. Government initiatives promoting IVF treatments create numerous expansion opportunities. However, high costs associated with IVF treatments and PGT procedures can be a major deterrent to potential end-users. Ethical concerns surrounding PGT and limited insurance coverage for IVF treatments hinder the adoption of PGT services. Major biotechnology companies are rapidly expanding efforts to combat ethical and regulatory challenges and creating technologies that take moral and ethical issues under consideration. New approaches such as next-generation sequencing (NGS) and non-invasive preimplantation testing are emerging technologies that offer significant potential for the growth of the technology.
Regional Insights
The Americas exhibit a high need for preimplantation genetic testing (PGT) owing to rising infertility rates caused by lifestyle changes and increasing awareness regarding genetic testing. Well-established healthcare infrastructure facilities and favorable reimbursement policies have made PGT services more accessible to couples seeking infertility treatments in the Americas. Companies in the region have strong R&D capabilities and government support that drive innovation in the field. Asia is emerging as a big and opportunistic market for PGT owing to improved provision of advanced fertility techniques such as IVF with PGT services and growing medical tourism, attracting international patients seeking cost-effective treatment options. Europe contributes significantly to the global PGT market due to factors such as increased government funding for healthcare research and widespread adoption of IVF procedures across various European countries. Moreover, stringent regulatory frameworks surrounding genetic testing ensure quality control and ethical considerations when implementing PGT services. Key players within this region contribute significantly to technological advancements in preimplantation genetic testing practices.
Market Insights
- Market Dynamics
The market dynamics represent an ever-changing landscape of the Preimplantation Genetic Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.- Market Drivers
- Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
- Increase in the rate of infertility and the rising number of fertility clinics worldwide
- Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
- Market Restraints
- Limitation and risks associated with PGT
- Market Opportunities
- Technological advancement in the field of preimplantation genetic analysis
- Emerging startup ecosystem and investments in the field of preimplantation genetic testing
- Market Challenges
- Ethical constraints and Misuse of PGT
- Market Segmentation Analysis
- Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
- Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
- Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
- Application: Wide use of preimplantation genetic testing for aneuploidy disorder
- End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Preimplantation Genetic Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Preimplantation Genetic Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments- Thermo Fisher Unveils Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit
Thermo Fisher Scientific introduced two new reproductive health tests, namely the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit. The newly introduced tests aim to revolutionize fertility research and contribute to the improvement of future generations' health.
Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
Kindbody, a fertility network and benefits provider, announced the launch of Kindlabs, its in-house genetic testing division. Kindlabs offers a comprehensive range of genetic tests that adhere to stringent quality standards, aiming to optimize the chances of a successful pregnancy.
Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
Medicover Genetics and Medicover Diagnostics Finland partnered with Fimlab Laboratories to offer genetic testing services to patients in Finland. This partnership is a significant milestone for Medicover Genetics as they continue to seek strategic collaborations and expand their services to new regions.
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Preimplantation Genetic Testing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..
Market Segmentation & Coverage
This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:- Technology
- Comparative Genomic Hybridization
- Fluorescence in-Situ Hybridization
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Single-Nucleotide Polymorphism
- Offering
- Instruments
- Reagents & Consumables
- Software & Services
- Procedure Type
- Preimplantation Genetic Diagnosis
- Preimplantation Genetic Screening
- Application
- Aneuploidy
- Gender Identification
- HLA Typing
- Single Gene Disorders
- Structural Chromosomal Abnormalities
- Deletions
- Duplications
- Inversions
- Translocations
- X-Linked Disorders
- End User
- Contract Research & Manufacturing Organizations
- Cryobanks
- Hospitals, Diagnostic Labs, & Service Providers
- Research Laboratories & Academic Institutes
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Please Note: PDF & Excel + Online Access - 1 Year
- Americas
- Market Drivers
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
- 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
- 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
- 5.1.2. Restraints
- 5.1.2.1. Limitation and risks associated with PGT
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
- 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
- 5.1.4. Challenges
- 5.1.4.1. Ethical constraints and Misuse of PGT
- 5.2. Market Segmentation Analysis
- 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
- 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
- 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
- 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
- 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
- 5.3. Market Trend Analysis
- 5.3.1. Presence of established companies and startups launching innovative preimplantation genetic solutions across the Americas
- 5.3.2. Supportive Government initiatives and the increasing infertility rate emphasized preimplantation genetic testing adoption in APAC
- 5.3.3. Rising adoption of preimplantation genetic testing for IVF across Europe and potential of global player expansion in Middle East & Africa
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework Analysis
- 6. Preimplantation Genetic Testing Market, by Technology
- 6.1. Introduction
- 6.2. Comparative Genomic Hybridization
- 6.3. Fluorescence in-Situ Hybridization
- 6.4. Next-Generation Sequencing
- 6.5. Polymerase Chain Reaction
- 6.6. Single-Nucleotide Polymorphism
- 7. Preimplantation Genetic Testing Market, by Offering
- 7.1. Introduction
- 7.2. Instruments
- 7.3. Reagents & Consumables
- 7.4. Software & Services
- 8. Preimplantation Genetic Testing Market, by Procedure Type
- 8.1. Introduction
- 8.2. Preimplantation Genetic Diagnosis
- 8.3. Preimplantation Genetic Screening
- 9. Preimplantation Genetic Testing Market, by Application
- 9.1. Introduction
- 9.2. Aneuploidy
- 9.3. Gender Identification
- 9.4. HLA Typing
- 9.5. Single Gene Disorders
- 9.6. Structural Chromosomal Abnormalities
- 9.7. X-Linked Disorders
- 10. Preimplantation Genetic Testing Market, by End User
- 10.1. Introduction
- 10.2. Contract Research & Manufacturing Organizations
- 10.3. Cryobanks
- 10.4. Hospitals, Diagnostic Labs, & Service Providers
- 10.5. Research Laboratories & Academic Institutes
- 11. Americas Preimplantation Genetic Testing Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Preimplantation Genetic Testing Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Preimplantation Genetic Testing Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. Market Share Analysis, 2023
- 14.2. FPNV Positioning Matrix, 2023
- 14.3. Competitive Scenario Analysis
- 14.3.1. Thermo Fisher Unveils Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit
- 14.3.2. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
- 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
- 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
- 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
- 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
- 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
- 14.3.8. Australia’s Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.2. Key Product Portfolio
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
